Start Your Search
A.C. Vethencourt Casado
P1.07 - Immunology and Immunotherapy (ID 693)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
P1.07-028 - Determination of Soluble PD-L1 as a Potential Biomaker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC) (ID 9781)
09:30 - 16:00 | Author(s): A.C. Vethencourt Casado
PD-L1 has been established as a predictive marker for anti-PD(L)1 treatment, although patients negative for PD-L1 may also respond to those treatments. Soluble PD-L1 (sPD-L1) in blood has been described as prognostic factor in advanced NSCLC. To date, no evidence of efficacy of anti-PD(L)1 treatment according to sPD-L1 has been reported. The objective of this study is the correlate the efficacy of anti-PD(L)1 treatment according to sPD-L1 in our patients.
Baseline sPL-L1 levels were prospectively determined in pretreated advanced NSCLC patients receiving anti-PD(L)1 treatment. sPD-L1 levels (high (H) and low (L)), were calculated based on the median value of sPD-L1, and those values were correlated with OS and PFS for all patients and for according to histology. sPD-L1 levels were also correlated with leucocyte and platelet count and PD-L1 expression in tumor.
In patients with adenocarcinoma, a positive correlation was observed between sPD-L1 levels and monocyte count (R:0.44; p: 0.0008), and with the ratio platelet/lymphocyte (R:0.55; p<0.0001). In all NSCLC patients and squamous cell carcinoma, a positive correlation was observed between sPD-L1 levels and neutrophil count (R:0.42; p: 0.002 and R:0.59; p: 0.0025 respectively). No correlation between sPD-L1 level and PD-L1 expression in tumor was observed (n: 22 patients; p: 0.9065)
sPD-L1 OS (m) PFS (m) H L H L Adenocarcinoma (n: 19) 10.3 (5.3-17.4) 14.3 (10.1-18.5) 5.8 (0.9-10.7) 8.7 (4.0-13.4) P 0.7 P: 0.7 Squamous cell carcinoma (n: 11) 16.1 (7.5-24.8) 14.7 (9.4-20.0) 11.4 (2.5-20.3) 6.9 (3.2-10.7) P: 0.8 P:0.7 All (n:30) 13.2 (9.2-17.2) 15.4 (12.0-18.9) 4.2 (0.4-7.9) 6.0 (0.6-11.3) P: 0.2 P: 0.5
Although no significant differences in OS or PFS were observed according to sPD-L1, a trend to a better OS was seen in NSCLC patients with low sPD-L1, especially in patients with adenocarcinoma. Prospective studies analyzing sPD-L1 levels and other PD-L1 variants are needed to find possible new biomarkers for anti-PD(L)1 treatments in NSCLC.